As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.
Bret Parker
Advertisement
Bret Parker is SVP, pharma solutions, at Prescryptive Health.
Articles by Bret Parker
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why UPS Committed $48M to Cold-Chain Cross-Dock Buildout
2
Payers Want Real-World Evidence. Why Aren't They Using It?
3
Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?
4
Why the Direct Access Channel Is No Longer Optional for Pharma
5